Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and tolerability of SP-02L monotherapy in Korean patients with relapsed or refractory Peripheral T-cell Lymphoma (PTCL).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Solasia Pharma K.K.
Collaborators
NCT03922724 · Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, and more
NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more
NCT06561048 · Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, and more
NCT06909877 · Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL)
NCT07283822 · Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, and more
Samsung Medical Center
Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions